We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Arcus Biosciences on Wednesday said a Phase II study testing combinations of its anti-TIGIT monoclonal antibody domvanalimab (AB154), which is partnered with Gilead Sciences, showed "encouraging" results when given as first-line treatment .